EECP appears safe when applied as adjunct therapy for heart failure. The efficacy results of this study must be viewed with care, as the size of the study population was small and comparisons were ...

All patients had LVEF ≤35% (mean, about 26%) despite optimal medical therapy. Patients were randomized to EECP plus optimal pharmacologic therapy for 7 weeks (n = 93) or optimal pharmacologic ...

The EECP has been shown to be safe and to have benefits for the treatment of heart failure, with 80 per cent of patients who complete the 35-hour course of therapy experiencing significant symptom ...